|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We provide the first evidence that aberrant expression of BRG1 and BRM genes is associated with disease development and progression in prostate cancers and increased BRG1 expression may promote tumor growth and invasion.
|
17075831 |
2007 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
• SMARCA4-DTS, which is mostly located in the chest cavity, can compress and infiltrate all adjacent organs leading to superior vena syndrome, lung atelectasis, epiduritis, spinal cord compression, and esophagus invasion.
|
30762113 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, restoring WNT3A expression rescues the inhibition of cell proliferation and invasion induced by BRG1.
|
27852072 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
BRG1 over-expression potentiated whereas BRG1 knockdown attenuated prostate cancer cell migration and invasion.
|
31154107 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Knockdown of Brg-1 by small interfering RNA led to decreased RNF43 expression, increased Wnt signaling and increased CRC cell migration and invasion.
|
25961913 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the BRG1-RAD52 complex mediates the replacement of RPA with RAD51 on single-stranded DNA (ssDNA) to initiate DNA strand invasion.
|
25395584 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Over-expression of BRG1 potentiated whereas depletion of BRG1 attenuated migration and invasion of MCF-7 cells.
|
30824191 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Finally, BRG1 restoration significantly dampened invasion and progression and decreased MYC in lung cancer cells orthotopically implanted in nude mice.
|
22407764 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Treatment with HDAC inhibitors or introduction of exogenous Brm into Brm-deficient cell lines significantly reduced the oncogenic potential as assessed by colony-forming activity in soft agar or invasion into collagen gel, indicating that, like BRG1, Brm is involved in tumor suppression.
|
16007216 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Using tissue microarray and immunohistochemistry, we evaluated BRG1 staining in 437 breast cancer specimens and investigated its role in breast cancer cell proliferation, migration and invasion.
|
23533649 |
2013 |
|
Triple-Negative Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our work suggests that targeting BRG1 to reduce lipid metabolism and, thereby, to reduce proliferation, has promise for epigenetic therapy in triple negative breast cancer.
|
27223259 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We demonstrate that knockdown of BRG1 sensitized triple negative breast cancer cells to chemotherapeutic drugs used to treat breast cancer.
|
27029062 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our work suggests that targeting BRG1 to reduce lipid metabolism and, thereby, to reduce proliferation, has promise for epigenetic therapy in triple negative breast cancer.
|
27223259 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.020 |
Biomarker
|
disease |
BEFREE |
We demonstrate that knockdown of BRG1 sensitized triple negative breast cancer cells to chemotherapeutic drugs used to treat breast cancer.
|
27029062 |
2016 |
|
Tooth Attrition
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This attrition was delayed by ectopic over-expression of Brg1 and was reproduced by inhibiting Brg1 activity either through genetic manipulation or treatment with the chemical inhibitor, (E)-1-(2-Hydroxyphenyl)-3-((1R, 4R)-5-(pyridin-2-yl)-2, 5-diazabicyclo[2.2.1]heptan-2-yl)prop-2-en-1-one, demonstrating the importance of Brg1 to maintenance of dendritic architecture.
|
28973294 |
2017 |
|
Thymoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Genes in histone modification [BAP1 (n = 6; 13%), SETD2 (n = 5; 11%), ASXL1 (n = 2; 4%)], chromatin remodeling [SMARCA4 (n = 2; 4%)], and DNA methylation [DNMT3A (n = 3; 7%), TET2 (n = 2; 4%), WT1 (n = 2; 4%)] pathways were recurrently mutated in TCs, but not in thymomas.
|
25482724 |
2014 |
|
Thymic Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Genes in histone modification [BAP1 (n = 6; 13%), SETD2 (n = 5; 11%), ASXL1 (n = 2; 4%)], chromatin remodeling [SMARCA4 (n = 2; 4%)], and DNA methylation [DNMT3A (n = 3; 7%), TET2 (n = 2; 4%), WT1 (n = 2; 4%)] pathways were recurrently mutated in TCs, but not in thymomas.
|
25482724 |
2014 |
|
Thymic Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
All thymic carcinomas showed retained BRG1 and INI-1.
|
28643792 |
2017 |
|
Thoracic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.
|
26343384 |
2015 |
|
Thick nasal alae
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Thick lower lip vermilion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Thick eyebrow
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Synovial Cyst
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that RGCs treated with HG exhibited a low expression level of Brg1 compared with untreated RGCs.
|
31101335 |
2019 |
|
Superficial ulcer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, all groups were subjected to a 5-day erosion cycle intercalating demineralization (1 min; 1% citric acid; pH = 3.5) and treatment with toothpaste slurries (2 min) of NaF, SnF2, F/Sn/Chitosan, F/CaSiO3/Na3PO4, and F/bioactive glass.
|
31800865 |
2019 |
|
Strabismus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|